This disclosure relates to the use of an implantable device to deliver biologically active compounds at a controlled rate for an extended period of time and methods of manufactures thereof. The device is biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.

A malleable polysaccharide soft tissue filler for filling tissue cavities or voids such as those resulting from tumor removal or other tissue resection. The soft tissue filler includes a first cross-linking polysaccharide, preferably a beta-D glucan and a second cross-linking polysaccharide. The soft tissue filler is both porous and malleable and can be formed to accommodate the tissue cavity or void. The soft tissue filler can include an embedded marker for locating on medical imaging. Methods of making the soft tissue filler including lyophilizing an aqueous polysaccharide suspension are disclosed. The second cross-linking polysaccharide provides for increased structural integrity in a high-porosity and malleable soft tissue filler in which the respective cross-linking polysaccharides synergistically provide structural scaffolding for one another. Methods of use are also disclosed.

The present invention relates to an ocular composition comprising a) at least 0.1% w/w of a therapeutic agent; b) 5 to 95% w/w of a photopolymerizable composition comprising 3 to 70% w/w of one or more compounds of formula I: (I) wherein R.sub.1 is hydrogen or a linear or branched C.sub.1-C.sub.3 alkyl; R.sub.2 is an acrylate or methacrylate group; n is 2 or 3 and m is equal or greater than 1, the weight percentage of the one or more compounds of formula I being based on the total weight of the photopolymerizable composition; c) 0.1 to 40% w/w of a biodegradable polymer selected from the group consisting of lactide/glycolide copolymer (including poly(lactide-co-glycolide) (PLGA)), poly (L-lactide) (PLA), polyhydroxyalkanoates, including polyhydroxybutyrate, polyglycolic acid (PGA), polycaprolactone (PCL), poly (DL-lactide) (PDL), poly (D-lactide), lactide/caprolactone copolymer,

Disclosed are methods of treating an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP. Disclosed are methods of preventing rupture of an aneurysm comprising administering to a subject having an aneurysm a composition comprising a SELP, wherein the SELP is present in the aneurysm and prevents rupture. Also disclosed are methods of embolizing an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising SEEP. Disclosed are methods of treating AVM in a subject comprising administering to the subject a composition comprising a SELP. In some aspects, the SELP embolizes an abnormal blood vessel in the AVM. Disclosed are methods of embolizing an AVM in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP, wherein the SELP embolizes an abnormal blood vessel in the AVM.

The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.

A bioelectronic device houses therapeutic cells and is configured to be implanted in a host. The device includes an electrochemical cell that produces oxygen gas from water when a voltage is applied. The oxygen gas produced by the electrochemical cell is stored in a gas diffusion chamber in the device. The therapeutic cells in a cell housing chamber in the device receive oxygen gas from the gas diffusion chamber to help keep the cells alive and functioning when the device is implanted in a low oxygen environment. The device receives power wirelessly.

Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.

Disclosed herein are compositions useful for treating hypogonadism in men and women. The disclosed compositions comprise an admixture of testosterone and triamcinolone which combination alleviates pellet injection site pain and/or discomfort, as well as pellet extrusion.

A stabilized active oxygen-generating antiseptic composition is disclosed including at least one of an antiseptic mixture or an antiseptic polymer. The antiseptic mixture includes a persulfate distributed in a matrix of a sulfate wherein the antiseptic composition is characterized by a ratio of the sulfate to the persulfate of at least 8:2. The antiseptic polymer is formed by the reaction of a sulfate, a persulfate, and amino acid in a reaction solution having a ratio of the sulfate to the persulfate of at least 6:4 and a ratio of the amino acid to the sulfate and the persulfate combined of 1:2 to 2:1. An antiseptic irrigation solution is disclosed including the antiseptic composition dispersed in a solvent. An antiseptic article is disclosed including an article and at least one of the antiseptic composition or an antiseptic coating formed from the antiseptic composition disposed on a surface of the article.

A hydrogel composition, a hydrogel biomedical material, a method for facilitating regeneration of a bone and a manufacturing method of a hydrogel composition are provided. The hydrogel composition includes a first deionized water, a gel powder, a transglutaminase mixture and a hyaluronic acid powder. The gel powder includes gelatin and alginic acid. The first deionized water, the gel powder, the transglutaminase mixture and the hyaluronic acid powder are evenly mixed. Based on the hydrogel composition being 100 wt %, the first deionized water is 95 wt % to 98.46 wt %, the gel powder is 1 wt % to 3 wt %, the transglutaminase mixture is 0.04 wt % to 0.15 wt %, and the hyaluronic acid powder is 0.5 wt % to 1.5 wt %.